KALSIOM is a biotech company based in Brest, France, discovering and developing first-in-class therapies to treat inflammatory auto-immunes disorders (AID) involving B-cell dysfunction with a high medical need.The company is focusing on developing first-in-class monoclonal antibodies modulating calcium-signaling pathways in immune cells.